Cargando…

Current view on novel vaccine technologies to combat human infectious diseases

ABSTRACT: Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and producti...

Descripción completa

Detalles Bibliográficos
Autores principales: Matić, Zrinka, Šantak, Maja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661323/
https://www.ncbi.nlm.nih.gov/pubmed/34889981
http://dx.doi.org/10.1007/s00253-021-11713-0
_version_ 1784613343990906880
author Matić, Zrinka
Šantak, Maja
author_facet Matić, Zrinka
Šantak, Maja
author_sort Matić, Zrinka
collection PubMed
description ABSTRACT: Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re-emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1–3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines. KEY POINTS: • Vaccines of the new generation follow the minimalist strategy. • Some infectious diseases remain a challenge for the vaccine development. • The number of new vaccine candidates in the late phase clinical trials remains low.
format Online
Article
Text
id pubmed-8661323
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-86613232021-12-10 Current view on novel vaccine technologies to combat human infectious diseases Matić, Zrinka Šantak, Maja Appl Microbiol Biotechnol Mini-Review ABSTRACT: Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re-emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1–3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines. KEY POINTS: • Vaccines of the new generation follow the minimalist strategy. • Some infectious diseases remain a challenge for the vaccine development. • The number of new vaccine candidates in the late phase clinical trials remains low. Springer Berlin Heidelberg 2021-12-10 2022 /pmc/articles/PMC8661323/ /pubmed/34889981 http://dx.doi.org/10.1007/s00253-021-11713-0 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Mini-Review
Matić, Zrinka
Šantak, Maja
Current view on novel vaccine technologies to combat human infectious diseases
title Current view on novel vaccine technologies to combat human infectious diseases
title_full Current view on novel vaccine technologies to combat human infectious diseases
title_fullStr Current view on novel vaccine technologies to combat human infectious diseases
title_full_unstemmed Current view on novel vaccine technologies to combat human infectious diseases
title_short Current view on novel vaccine technologies to combat human infectious diseases
title_sort current view on novel vaccine technologies to combat human infectious diseases
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661323/
https://www.ncbi.nlm.nih.gov/pubmed/34889981
http://dx.doi.org/10.1007/s00253-021-11713-0
work_keys_str_mv AT maticzrinka currentviewonnovelvaccinetechnologiestocombathumaninfectiousdiseases
AT santakmaja currentviewonnovelvaccinetechnologiestocombathumaninfectiousdiseases